As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- Merck Receives FDA Approval for Fixed Dose Combination of Januvia, Simvastatin
October 12, 2011
- PACIFIC Study Finds Higher Rate of STEMI in ACS in Japanese
October 12, 2011
- Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
- Sales of Publicly Funded Vaccines Continue to Increase in August: Crecon Research & Consulting
October 11, 2011
- AZ to Reduce US HQ Staff by approx. 400
October 11, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Cubicin 350 mg IV Inj. Launched for MRSA Infections: MSD
October 10, 2011
- Results of PIII Trial of Rotarix Published in US Journal Vaccine: GSK
October 10, 2011
- Tsuruha HD to Establish Drugstore Joint Venture in Thailand
October 10, 2011
- Teva, Kowa to Break Up Joint Venture After Just 3 Years
October 10, 2011
- MediciNova Announces Private Sale of Stock to Kissei
October 10, 2011
- Novartis Pharma Donates ¥21 Mil. for Free Medical Exams for Disaster Victims in Soma City
October 10, 2011
- Telavic Approved for Chronic Hepatitis C: MTPC
October 10, 2011
- Anti-emetic Proemend IV Infusion 150 mg Approved: Ono
October 10, 2011
- Ilaris Approved as Japan’s 1st CAPS Treatment: Novartis Pharma
October 10, 2011
- Teribone Approved for Osteoporosis with High Fracture Risk: Asahi Kasei Pharma
October 10, 2011
- TachoSil Tissue Sealing Sheet Approved: CSL Behring
October 10, 2011
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…